Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (41-50 of 426) with videos related to

Pageof 43
Sort By:
Biologics : Targets & Therapy|August 27, 2009
Ranpirnase and its potential for the treatment of unresectable malignant mesotheliomaCamillo Porta, Chiara Paglino, Luciano Mutti
The Journal of Supportive Oncology|April 6, 2011
Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurseElizabeth Manchen, Caroline Robert, Camillo Porta
European Urology|December 28, 2007
Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;53:376-81Camillo Porta, Ilaria Imarisio, Chiara Paglino
European Urology|September 7, 2013
Slow and steady wins the race: practical (and philosophical) considerations of treatment activity evaluation when novel anticancer agents just slow neoplastic progressionCamillo Porta, Alessandro Vercelli, Chiara Paglino
Contributions to Nephrology|February 3, 2018
Acute Kidney Injury in Cancer PatientsMaurizio Gallieni, Laura Cosmai, Camillo Porta
Current Opinion in Urology|March 20, 2021
Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?Camillo Porta, Laura Cosmai, Mimma Rizzo
European Urology|November 29, 2024
Despite an Abundance of Active Treatment Options for Renal Cell Carcinoma, Shadows Still Obscure the LightCamillo Porta, Carlo Ganini, Mimma Rizzo
Clinical Therapeutics|February 13, 2017
Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service PerspectiveStefano Capri, Camillo Porta, Thomas E Delea
Seminars in Oncology|July 1, 2005
New agents in the management of advanced mesotheliomaNicholas J Vogelzang, Camillo Porta, Luciano Mutti
Critical Reviews in Oncology/Hematology|November 15, 2018
Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS ReviewSergio Bracarda, Camillo Porta, Roberto Sabbatini, et al.
Pageof 43

Showing results (41-50 of 426) with videos related to

Sort By:
Pageof 43
Biologics : Targets & Therapy|August 27, 2009
Ranpirnase and its potential for the treatment of unresectable malignant mesotheliomaCamillo Porta, Chiara Paglino, Luciano Mutti
The Journal of Supportive Oncology|April 6, 2011
Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurseElizabeth Manchen, Caroline Robert, Camillo Porta
European Urology|December 28, 2007
Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;53:376-81Camillo Porta, Ilaria Imarisio, Chiara Paglino
European Urology|September 7, 2013
Slow and steady wins the race: practical (and philosophical) considerations of treatment activity evaluation when novel anticancer agents just slow neoplastic progressionCamillo Porta, Alessandro Vercelli, Chiara Paglino
Contributions to Nephrology|February 3, 2018
Acute Kidney Injury in Cancer PatientsMaurizio Gallieni, Laura Cosmai, Camillo Porta
Current Opinion in Urology|March 20, 2021
Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?Camillo Porta, Laura Cosmai, Mimma Rizzo
European Urology|November 29, 2024
Despite an Abundance of Active Treatment Options for Renal Cell Carcinoma, Shadows Still Obscure the LightCamillo Porta, Carlo Ganini, Mimma Rizzo
Clinical Therapeutics|February 13, 2017
Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service PerspectiveStefano Capri, Camillo Porta, Thomas E Delea
Seminars in Oncology|July 1, 2005
New agents in the management of advanced mesotheliomaNicholas J Vogelzang, Camillo Porta, Luciano Mutti
Critical Reviews in Oncology/Hematology|November 15, 2018
Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS ReviewSergio Bracarda, Camillo Porta, Roberto Sabbatini, et al.
Pageof 43